All In Biotech

Drug Trial Radar · NCT05298787

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD/MAD Adaptive-Design Study to Assess the Safety, Tolerability, PK, and PD of RLS-0071 in Healthy Adult Subjects in Support of a COVID-19 Development Program

Last checked: Nov 19, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jan 13, 2021

Primary completion

Aug 16, 2021

Study completion Aug 16, 2021

Sponsor

Lead sponsor
ReAlta Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety, tolerability, PK, and PD of single- and multiple-ascending doses of RLS-0071 in healthy adult subjects.

Conditions

  • Healthy Volunteer

Interventions

  • RLS-0071Drug

    RLS-0071 is administered as an IV infusion

  • Saline PlaceboDrug

    Placebo is administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From initiation of study treatment (Day 1) through follow-up period (Day 30)
  2. Incidence of abnormal laboratory test resultsTime frame: From initiation of study treatment (Day 1) through follow-up period (Day 30)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.